deltatrials
Completed NCT00195299

Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck

An Exploratory Biomarker Trail of Temsirolimus in Subjects With Newly Diagnosed Advanced Stage Squamous Cell Carcinoma of the Head & Neck

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Squamous Cell Carcinoma
Interventions Temsirolimus
Updated 6 times since 2017 Last updated: Dec 18, 2007 Started: Apr 30, 2005 Completion: Feb 28, 2007

Listed as NCT00195299, this observational or N/A phase trial focuses on Squamous Cell Carcinoma and remains completed. Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed

  2. Jul 2024 — Sep 2024 [monthly]

    Completed

  3. Jan 2021 — Jul 2024 [monthly]

    Completed

  4. Jun 2018 — Jan 2021 [monthly]

    Completed

  5. Apr 2018 — Jun 2018 [monthly]

    Completed

    Phase: NA → None

▶ Show 1 earlier version

  1. Jan 2017 — Apr 2018 [monthly]

    Completed NA

    First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Wyeth is now a wholly owned subsidiary of Pfizer
Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Shreveport, United States